Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study

• Egile Nagusiak: Gilbert L'Italien (Egilea), Evan Popoff (Egilea), Karissa Johnston (Egilea), Donnie McGrath (Egilea), Charles M Conway (Egilea), Lauren Powell (Egilea), Linda Harris (Egilea), Nicole Kowalczyk (Egilea), Robert Croop (Egilea), Vladimir Coric (Egilea)
• Formatua: Liburua
• Argitaratua: SAGE Publishing, 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Rimegepant, a small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonist, is approved for the acute and preventive treatment of migraine. We hypothesized that intermittent CGRP receptor blockade with rimegepant 75 mg acute treatment as needed (PRN) might result in red...